Effects of the interaction between interleukin-6- 634C/G polymorphism and smoking on serum C-reactive protein concentrations

Hypertension Research

Volumn 30, Issue 7, 2007, Pages 593-599

  Saijo, Yasuaki ^a   Yoshioka, Eiji ^b   Fukui, Tomonori ^b   Kawaharada, Mariko ^b   Sata, Fumihiro ^b   Sato, Hirokazu ^c   Kishi, Reiko ^b  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c JR Sapporo Railway Hospital   (Japan)

Author keywords

C reactive protein; Gene polymorphism; Interaction; Interleukin 6; Smoking

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; CYTOSINE; GLUCOSE; GUANINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; TRIACYLGLYCEROL;

5' UNTRANSLATED REGION; ADULT; AGE DISTRIBUTION; ALLELE; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CONTROLLED STUDY; DRINKING BEHAVIOR; EMPLOYEE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PROMOTER REGION; PROTEIN BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ALLELES; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; HUMANS; INFLAMMATION; INTERLEUKIN-6; JAPAN; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; SMOKING;

EID: 34548011741     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.30.593     Document Type: Article

References (38)

1. Ross R: Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-126.
2. Ridker PM, Hennekens CH, Buring JE, Rifai N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-843.
3. Koenig W, Sund M, Frohlich M, et al: C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999; 99: 237-242.
4. Danesh J, Whincup P, Walker M, et al: Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ 2000; 321: 199-204.
5. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR: Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347: 1557-1565.
6. Heinrich PC, Castell JV, Andus T: Interleukin-6 and the acute phase response. Biochem J 1990; 265: 621-636.
7. Mendall MA, Patel P, Asante M, et al: Relation of serum cytokine concentrations to cardiovascular risk factors. and coronary heart disease. Heart 1997; 78: 273-277.
8. Berinudez EA, Rifai N, Buring J, Manson JE, Ridker PM: Interrelationships among circulating interleukin-6, C-reactive protein, and traditional cardiovascular risk factors in women. Arterioscler Thromb Vasc Biol 2002; 22: 1668-1673.
9. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB, European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group: Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet 1997; 349: 462-466.
10. Vickers MA, Green FR, Terry C, et al: Genotype at a promoter polymorphism of the interleukin-6 gene is associated with baseline levels of plasma C-reactive protein. Cardiovasc Res 2002; 53: 1029-1034.
11. Latkovskis G, Licis N, Kalnins U: C-reactive protein levels and common polymorphisms of the interleukin-1 gene cluster and interleukin-6 gene in patients with coronary heart disease. Eur J Immunogenet 2004; 31: 207-213.
12. Libra M, Signorelli SS, Bevelacqua Y, et al: Analysis of G(-174)C IL-6 polymorphism and plasma concentrations of inflammatory markers in patients with type 2 diabetes and peripheral arterial disease. J Clin Pathol 2006; 59: 211-215.
13. Ortlepp JR, Metrikat J, Vesper K, et al: The interleukin-6 promoter polymorphism is associated with elevated leukocyte, lymphocyte, and monocyte counts and reduced physical fitness in young healthy smokers. J Mol Med 2003; 81: 578-584.
14. Saijo Y, Sata F, Yamada H, Kondo T, Kato EH, Kishi R: Single nucleotide polymorphisms in the promoter region of the interleukin-6 gene and the risk of recurrent pregnancy loss in Japanese women. Fertil Steril 2004; 81: 374-378.
15. Hayakawa T, Takamura T, Hisada A, Abe T, Nomura G, Kobayashi K: IL-6 gene polymorphism -174G/C does not contribute substantially to hyperlipidaemia and type II diabetes mellitus in Japanese men. Diabetologia 2002; 45: 453-454.
16. Zhai R, Liu G, Yang C, Huang C, Wu C, Christiani DC: The G to C polymorphism at -174 of the interleukin-6 gene is rare in a Southern Chinese population. Pharmacogenetics 2001; 11: 699-701.
17. Lim CS, Zheng S, Kim YS, et al: The -174 G to C polymorphism of interleukin-6 gene is very rare in Koreans. Cytokine 2002; 19: 52-54.
18. Ota N, Nakajima T, Nakazawa I, et al: A nucleotide variant in the promoter region of the interleukin-6 gene associated with decreased bone mineral density. J Hum Genet 2001; 46: 267-272.
19. Kitamura A, Hasegawa G, Obayashi H, et al: Interleukin-6 polymorphism (-634C/G) in the promotor region and the progression of diabetic nephropathy in type 2 diabetes. Diabet Med 2002; 19: 1000-1005.
20. Saijo Y, Sata F, Yamada H, et al: Ah receptor, CYP1A1, CYP1A2 and CYP1B1 gene polymorphisms are not involved in the risk of recurrent pregnancy loss. Mol Hum Reprod 2004; 10: 729-733.
21. Makhseed M, Raghupathy R, Azizieh F, Farhat R, Hassan N, Bandar A: Circulating cytokines and CD30 in normal human pregnancy and recurrent spontaneous abortions. Hum Reprod 2000; 15: 2011-2017.
22. Ferrari SL, Ahn-Luong L, Garnero P, Humphries SE, Greenspan SL: Two promoter polymorphisms; regulating interleukin-6 gene expression are associated with circulating levels of C-reactive protein and markers of bone resorption in postmenopausal women. J Clin Endocrinol Metab 2003; 88: 255-259.
23. Hamid YH, Rose CS, Urhammer SA, et al: Variations of the interleukin-6 promoter are associated with features of the metabolic syndrome in Caucasian Danes. Diabetologia 2005; 48: 251-260.
24. Muller-Steinhardt M, Fricke L, Muller B, Ebel B, Kirchner H, Hartel C: Cooperative influence of the interleukin-6 promoter polymorphisms -597, -572 and -174 on long-term kidney allograft survival. Am J Transplant 2004; 4: 402-406.
25. Rivera-Chavez FA, Peters-Hybki DL, Barber RC, O'Keefe GE: Interleukin-6 promoter haplotypes and interleukin-6 cytokine responses. Shock 2003; 20: 218-223.
26. Fishman D, Faulds G, Jeffery R, et al: The effect of novel polyrnorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998; 102: 1369-1376.
27. Terry CF, Loukaci V, Green FR: Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J Biol Chem 2000; 275: 18138-18144.
28. Tanaka C, Mannami T, Kamide K, et al: Single nucleotide polymorphisms in the interleukin-6 gene associated with blood pressure and atherosclerosis in a Japanese general population. Hypertens Res 2005; 28: 35-41.
29. Saarikoski ST, Voho A, Reinikainen M, et al: Combined effect of polymorphic GST genes on individual susceptibility to lung cancer. Int J Cancer 1998; 77: 516-521.
30. Sasaki S, Kondo T, Sata F, et al: Maternal smoking during pregnancy and genetic polymorphisms in the Ah receptor, CYP1A1 and GSTM1 affect infant birth size in Japanese subjects. Mol Hum Reprod 2006; 12: 77-83.
31. Hayes JD, Pulford DJ: The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 1995; 30: 445-600.
32. Kim JH, Park SG, Lee KH, et al: GSTM1 and GSTP1 polymorphisms as potential factors for modifying the effect of smoking on inflammatory response. J Korean Med Sci 2006; 21: 1021-1027.
33. Jones KG, Brull DJ, Brown LC, et al: Interleukin-6 (IL-6) and the prognosis of abdominal aortic aneurysms. Circulation 2001; 103: 2260-2265.
34. Brull DJ, Montgomery HE, Sanders J, et al: Interleukin-6 gene -174g>c and -572g>c promoter polymorphisms are strong predictors of plasma interleukin-6 levels after coronary artery bypass surgery. Arterioscler Thromb Vasc Biol 2001; 21: 1458-1463.
35. Tiret L: Gene-environment interaction: a central concept in multifactorial diseases. Proc Nutr Soc 2002; 61: 457-463.
36. Bazzano LA, He J, Muntner P, Vupputuri S, Whelton PK: Relationship between cigarette smoking and novel risk factors for cardiovascular disease in the United States. Ann Intern Med 2003; 138: 891-897.
37. Albert MA, Danielson E, Rifai N, Ridker PM: Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001; 286: 64-70.
38. DeMichele A, Martin AM, Mick R, et al: Interleukin-6 -174G→C polymorphism is associated with improved outcome in high-risk breast cancer. Cancer Res 2003; 63: 8051-8056.